bloodjourГематология и трансфузиологияRussian journal of hematology and transfusiology0234-57302411-3042ООО Издательский дом «Практика»10.35754/0234-5730-2024-69-2-140-152bloodjour-543Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESРезультаты лечения лимфобластных лимфом из клеток-предшественниц по протоколам «ALL IC-BFM 2002/2009» в рамках моноцентрового клинического исследованияTreatment results of lymphoblastic lymphomas from progenitor cells according to ALL IC-BFM 2002/2009 protocols: monocenter clinical trialhttps://orcid.org/0000-0003-4999-5195ПавловаТ. Ю.PavlovaT. Yu.

Павлова Татьяна Юрьевна, гематолог отделения детской онкологии и  гематологии (химиотерапии гемобластозов) № 1

115522, г. Москва

Tatyana Y. Pavlova, Hematologist of the Department of Pediatric Oncology and Hematology (Hemoblastosis Chemotherapy) No. 1

24 Kashirskoye Shosse, Moscow 115522

md.pavlovaty@mail.ruhttps://orcid.org/0000-0002-1469-2365ВалиевТ. Т.ValievT. T.

Валиев Тимур Теймуразович, доктор медицинских наук, заведующий отделением детской онкологии и гематологии (химиотерапии гемобластозов) № 1

115522, г. Москва

Timur T. Valiev,  Dr. Sci. (Med.), Head of the Department of Pediatric Oncology and Hematology (Chemotherapy of Hemoblastosis) №1

24 Kashirskoye Shosse, Moscow 115522

timurvaliev@mail.ruВарфоломееваС. Р.VarfolomeevaS. R.

Варфоломеева Светлана Рафаэлевна,  доктор медицинских наук, профессор, директор

115522, г. Москва

Svetlana R. Varfolomeeva,  Dr. Sci. (Med.), Professor, Director

24 Kashirskoye Shosse, Moscow 115522

s.varfolomeeva@ronc.ruНИИ детской онкологии и гематологии ФГБУ «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Министерства здравоохранения Российской ФедерацииРоссияPediatric Oncology and Hematology Research Institute of N.N. Blok hin National Medical Research Center of Oncology, Ministry of Health of the RussiaRussian Federation202417082024692140152Copyright © Павлова Т.Ю., Валиев Т.Т., Варфоломеева С.Р., 20242024Павлова Т.Ю., Валиев Т.Т., Варфоломеева С.Р.Pavlova T.Y., Valiev T.T., Varfolomeeva S.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.htjournal.ru/jour/article/view/543Введение

Введение. Программы терапии острого лимфобластного лейкоза, разработанные группой BFM (Berlin-Frankfurt-Munster), используют для лечения лимфобластных лимфом из  клеток-предшественниц (ЛБЛ), они являются одним из наиболее эффективных методов лечения.

Цель

Цель: оценить результаты лечения ЛБЛ у  детей по  протоколам «ALL  IC-BFM 2002/2009» в  рамках клинического исследования одного центра.

Материалы и методы

Материалы и методы.  С 2002 по 2022 г. в ретроспективно-проспективное исследование включено 70 больных в возрасте от 2 до 17 лет с впервые установленным диагнозом ЛБЛ, медиана возраста составила 9,4 года, из них 43 больных мужского пола и 27 — женского. ЛБЛ из Т-клеток-предшественниц (Т-ЛБЛ) диагностирована у 61 (87 %) больного, В-ЛБЛ — у 9 (13 %). В группу среднего риска вошли 59 (84,3 %) больных, высокого риска — 11 (15,7 %). Не было больных, соответствовавших критериям для группы стандартного риска.

Результаты

Результаты. Десятилетняя общая выживаемость (ОВ) в группе больных, получивших лечение по протоколам «ALL IC-BFM 2002/2009», составила 95,4 ± 2,6 %; 10-летняя безрецидивная выживаемость — 91,9 ± 4,9 %; 10-летняя бессобытийная выживаемость — 86,7 ± 5,6 %. При анализе показателей выживаемости в зависимости от прогностической группы риска оказалось, что 10-летняя ОВ для больных группы среднего риска составила 96,6 ± 2,6 %, а для больных группы высокого риска — 90,9 ± 8,7 %.

Выводы

Выводы.  Результаты подтверждают высокую эффективность протоколов «ALL IC- BFM 2002/2009» в лечении ЛБЛ.

Introduction

Introduction.  The acute lymphoblastic leukemia (ALL) therapy programs developed by the BFM group (Berlin-Frankfurt-Munster) are used to treat lymphoblastic lymphomas from precursor cells (LBL) and are the most effective treatment methods in the world.

Aim

Aim. To assess   the treatment results of LBL in children according to the ALL IC-BFM 2002/2009 protocols in a clinical trial of a single center.

Materials and methods

Materials and methods. From 2002 to 2022 a retrospective and prospective study included 70 patients aged 2 to 17 years with newly diagnosed LBL, with a median age of 9.4 years. There were 1.5 times more male patients than female (43:27). LBL from T-cells progenitor (T-LBL) was diagnosed in 61 patients (87 %), and LBL from B-cells progenitor (B-LBL) — in 9 (13 %). 59 (84.3 %) patients were included in the intermediate risk (IR) group and 11 (15.7 %) patients — in high-risk (HR) group. There were no patients in the study cohort who met the criteria of the standard risk group (SR).

Results

Results. The 10-year OS in the group of patients treated according to the ALL IC-BFM 2002/2009 protocols was 95.4 ± 2.6 %; the 10-year RFS — 91.9 ± 4.9 %; the 10-year EFS — 86.7 ± 5.6 %. When analyzing survival rates depending on the prognostic risk group, the 10-year OS for patients of the intermediate risk group was 96.6 ± 2.6 %, and for patients of the high-risk group — 90.9 ± 8.7 %.

Conclusions

Conclusions. The obtained results confirm the high effectiveness of  the ALL IC-BFM 2002/2009 protocols in the treatment of LBL.

лимфобластные лимфомыдетиподросткитерапияlymphoblastic lymphomaschildrenadolescentstherapyReferencesFelix H., Ougier J., Pirollet H., et al. Leucosarcomatose de Sternberg. (a propos de 7 observations). Lyon Med. 1964; 211: 1047–97.Felix H., Ougier J., Pirollet H., et al. Leucosarcomatose de Sternberg. (a propos de 7 observations). Lyon Med. 1964; 211: 1047–97.Barcos M.P., Lukes R.J. Malignant lymphoma of convoluted lymphocytes: A new entity of possible T-cell type. In: Conflicts in Childhood Cancer. Sinks L.F, Godden J.E. (eds.). New York: Alan R. Liss 1975. 147 p.Barcos M.P., Lukes R.J. Malignant lymphoma of convoluted lymphocytes: A new entity of possible T-cell type. In: Conflicts in Childhood Cancer. Sinks L.F, Godden J.E. (eds.). New York: Alan R. Liss 1975. 147 p.Burkhardt B., Zimmermann M., Oschlies I., et al. BFM Group. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol. 2005; 131(1): 39–49. DOI: 10.1111/j.1365-2141.2005.05735.x.Burkhardt B., Zimmermann M., Oschlies I., et al. BFM Group. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol. 2005; 131(1): 39–49. DOI: 10.1111/j.1365-2141.2005.05735.x.Oschlies I., Burkhardt B., Chassagne-Clement С., et al. Diagnosis and immunophenotype of 188 pediatric lymphoblastic lymphomas treated within a randomized prospective trial: experiences and preliminary recommendations from the European childhood lymphoma pathology panel. Am J Surg Pathol. 2011; 35(6): 836–44. DOI: 10.1097/PAS.0b013e318213e90e.Oschlies I., Burkhardt B., Chassagne-Clement С., et al. Diagnosis and immunophenotype of 188 pediatric lymphoblastic lymphomas treated within a randomized prospective trial: experiences and preliminary recommendations from the European childhood lymphoma pathology panel. Am J Surg Pathol. 2011; 35(6): 836–44. DOI: 10.1097/PAS.0b013e318213e90e.Termuhlen A.M., Smith L.M., Perkins S.L., et al. Disseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the Children’s Oncology Group. Br J Haematol. 2013; 162(6): 792–801. DOI: 10.1111/bjh.12460.Termuhlen A.M., Smith L.M., Perkins S.L., et al. Disseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the Children’s Oncology Group. Br J Haematol. 2013; 162(6): 792–801. DOI: 10.1111/bjh.12460.Landmann E., Burkhardt B., Zimmermann M., et al. Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma. Haematologica. 2017; 102(12): 2086–96. DOI: 10.3324/haematol.2015.139162.Landmann E., Burkhardt B., Zimmermann M., et al. Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma. Haematologica. 2017; 102(12): 2086–96. DOI: 10.3324/haematol.2015.139162.Schmidt E., Burkhardt B. Lymphoblastic lymphoma in childhood and adolescence. Pediatr Hematol Oncol. 2013; 30(6): 484–508. DOI: 10.3109/08880018.2013.789574.Schmidt E., Burkhardt B. Lymphoblastic lymphoma in childhood and adolescence. Pediatr Hematol Oncol. 2013; 30(6): 484–508. DOI: 10.3109/08880018.2013.789574.Alaggio R., Amador C., Anagnostopoulos I., et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7): 1720–48. DOI: 10.1038/s41375-023-01962-5.Alaggio R., Amador C., Anagnostopoulos I., et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7): 1720–48. DOI: 10.1038/s41375-023-01962-5.Rosolen A., Perkins S.L., Pinkerton C.R., et al. Revised International Pediatric Non-Hodgkin Lymphoma Staging System. J Clin Oncol. 2015; 33(18): 2112–8. DOI: 10.1200/JCO.2014.59.7203.Rosolen A., Perkins S.L., Pinkerton C.R., et al. Revised International Pediatric Non-Hodgkin Lymphoma Staging System. J Clin Oncol. 2015; 33(18): 2112–8. DOI: 10.1200/JCO.2014.59.7203.Вurkhardt B., Bruch J., Zimmermann M., et al. Loss of heterozygosity on chromosome 6q14-q24 is associated with poor outcome in children and adolescents with T-cell lymphoblastic lymphoma. Leukemia. 2006; 20(8): 1422–9. DOI: 10.1038/sj.leu.2404275.Вurkhardt B., Bruch J., Zimmermann M., et al. Loss of heterozygosity on chromosome 6q14-q24 is associated with poor outcome in children and adolescents with T-cell lymphoblastic lymphoma. Leukemia. 2006; 20(8): 1422–9. DOI: 10.1038/sj.leu.2404275.Basso K., Mussolin L., Lettieri A., et al. T-cell lymphoblastic lymphoma shows differences and similarities with T-cell acute lymphoblastic leukemia by genomic and gene expression analyses. Genes Chromosomes Cancer. 2011; 50(12): 1063–75. DOI: 10.1002/gcc.20924.Basso K., Mussolin L., Lettieri A., et al. T-cell lymphoblastic lymphoma shows differences and similarities with T-cell acute lymphoblastic leukemia by genomic and gene expression analyses. Genes Chromosomes Cancer. 2011; 50(12): 1063–75. DOI: 10.1002/gcc.20924.Feng H., Stachura D.L., White R.M., et al. T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation. Cancer Cell. 2010; 18(4): 353–66. DOI: 10.1016/j.ccr.2010.09.009.Feng H., Stachura D.L., White R.M., et al. T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation. Cancer Cell. 2010; 18(4): 353–66. DOI: 10.1016/j.ccr.2010.09.009.Meyer J.A., Zhou D., Mason C.C., et al. Genomic characterization of pediatric B-lymphoblastic lymphoma and B-lymphoblastic leukemia using formalin-fixed tissues. Pediatr Blood Cancer. 2017; 64(7). DOI: 10.1002/pbc.26363.Meyer J.A., Zhou D., Mason C.C., et al. Genomic characterization of pediatric B-lymphoblastic lymphoma and B-lymphoblastic leukemia using formalin-fixed tissues. Pediatr Blood Cancer. 2017; 64(7). DOI: 10.1002/pbc.26363.Pui C., Roberts K., Yang J., et al. Philadelphia Chromosome-like Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2017; 17(8): 464–70. DOI: 10.1016/j.clml.2017.03.299.Pui C., Roberts K., Yang J., et al. Philadelphia Chromosome-like Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2017; 17(8): 464–70. DOI: 10.1016/j.clml.2017.03.299.Knez V., Bao L., Carstens B., et al. Analysis of clinicopathological and cytogenetic differences between B-lymphoblastic lymphoma and B-lymphoblastic leukemia in childhood. Leuk Lymphoma. 2020; 61(9): 2129–35. DOI: 10.1080/10428194.2020.1761970.Knez V., Bao L., Carstens B., et al. Analysis of clinicopathological and cytogenetic differences between B-lymphoblastic lymphoma and B-lymphoblastic leukemia in childhood. Leuk Lymphoma. 2020; 61(9): 2129–35. DOI: 10.1080/10428194.2020.1761970.Hoelzer D., Gokbuget N., Digel W., et al. Outcome of adult patients with Tlymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood. 2002; 99(12): 4379–85. DOI: 10.1182/blood-2002-01-0110.Hoelzer D., Gokbuget N., Digel W., et al. Outcome of adult patients with Tlymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood. 2002; 99(12): 4379–85. DOI: 10.1182/blood-2002-01-0110.Reiter A., Schrappe M., Ludwig W.D, et al. Intensive ALL type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood. 2000; 95(2): 416–21.Reiter A., Schrappe M., Ludwig W.D, et al. Intensive ALL type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood. 2000; 95(2): 416–21.Patte C., Kalifa C., Flamant F., et al. Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-Bcell (lymphoblastic) lymphoma. Med Pediatr Oncol. 1992; 20(2): 105–13. DOI: 10.1002/mpo.2950200204.Patte C., Kalifa C., Flamant F., et al. Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-Bcell (lymphoblastic) lymphoma. Med Pediatr Oncol. 1992; 20(2): 105–13. DOI: 10.1002/mpo.2950200204.Dahl G.V., Rivera G., Pui C.H., et al. A novel treatment of childhood lymphoblastic non-Hodgkin’s lymphoma: early and intermittent use of teniposide plus cytarabine. Blood. 1985; 66(5): 1110–4.Dahl G.V., Rivera G., Pui C.H., et al. A novel treatment of childhood lymphoblastic non-Hodgkin’s lymphoma: early and intermittent use of teniposide plus cytarabine. Blood. 1985; 66(5): 1110–4.Weinstein H.J, Cassady J.R, Levey R. Long-term results of the APO protocol (vincristine, doxorubicin [adriamycin], and prednisone) for treatment of mediastinal lymphoblastic lymphoma. J Clin Oncol. 1983; 1(9): 537–41.Weinstein H.J, Cassady J.R, Levey R. Long-term results of the APO protocol (vincristine, doxorubicin [adriamycin], and prednisone) for treatment of mediastinal lymphoblastic lymphoma. J Clin Oncol. 1983; 1(9): 537–41.Wollner N., Burchenal J.H., Lieberman P.H., et al. Non-Hodgkin’s lymphoma in children. A comparative study of two modalities of therapy. Cancer. 1976; 37(1): 123–34. DOI: 10.1002/1097-0142(197601)37:1<123::aidcncr2820370119>3.0.co;2-7.Wollner N., Burchenal J.H., Lieberman P.H., et al. Non-Hodgkin’s lymphoma in children. A comparative study of two modalities of therapy. Cancer. 1976; 37(1): 123–34. DOI: 10.1002/1097-0142(197601)37:1<123::aidcncr2820370119>3.0.co;2-7.Cortelazzo S., Ferreri A., Hoelzer D., et al. Lymphoblastic lymphoma. Crit Rev Oncol Hematol. 2017; 113: 304–17. DOI: 10.1016/j.critrevonc.2017.03.020.Cortelazzo S., Ferreri A., Hoelzer D., et al. Lymphoblastic lymphoma. Crit Rev Oncol Hematol. 2017; 113: 304–17. DOI: 10.1016/j.critrevonc.2017.03.020.Wollner N., Exelby R., Lieberman P.H. Non-Hodgkin’s lymphoma in children: a progress report on the original patients treated with the LSA2-L2 protocol. Cancer. 1979; 44(6): 1990–9. DOI: 10.1002/1097-0142(197912)44:6<1990::aidcncr2820440605>3.0.co;2-9.Wollner N., Exelby R., Lieberman P.H. Non-Hodgkin’s lymphoma in children: a progress report on the original patients treated with the LSA2-L2 protocol. Cancer. 1979; 44(6): 1990–9. DOI: 10.1002/1097-0142(197912)44:6<1990::aidcncr2820440605>3.0.co;2-9.Валиев Т.Т., Шервашидзе М.А., Осипова И.В. и др. Протокол ALL-IC BFM 2002: результаты лечения острого лимфобластного лейкоза у детей в рамках многоцентрового клинического исследования. Клиническая онкогематология. 2022; 15(2): 119–29. DOI: 10.21320/2500-2139-2022-15-2-119-129.Valiev T.T., Shervashidze M.A., Osipova I.V., et al. ALL-IC BFM Protocol 2002: results of treatment of acute lymphoblastic leukemia in children in a multicenter clinical trial. Klinicheskaya Onkogematologiya. 2022; 15(2): 119–29 (In Russian). DOI: 10.21320/2500-2139-2022-15-2-119-129.Burkhardt B., Hermiston M.L. Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities. Br J Haematol. 2019; 185(6): 1158–70. DOI: 10.1111/bjh.15793.Burkhardt B., Hermiston M.L. Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities. Br J Haematol. 2019; 185(6): 1158–70. DOI: 10.1111/bjh.15793.Campbell M., Kiss C., Zimmermann M., et al. Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Munster 2009 Trial. J Clin Oncol. 2023; 41(19): 3499–511. DOI: 10.1200/JCO.22.01760.Campbell M., Kiss C., Zimmermann M., et al. Childhood Acute Lymphoblastic Leukemia: Results of the Randomized Acute Lymphoblastic Leukemia Intercontinental-Berlin-Frankfurt-Munster 2009 Trial. J Clin Oncol. 2023; 41(19): 3499–511. DOI: 10.1200/JCO.22.01760.Temple W.C., Mueller S., Hermiston M.L., et al. Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young adults. Best Pract Res Clin Haematol. 2023; 36(1): 101449. DOI: 10.1016/j.beha.2023.101449.Temple W.C., Mueller S., Hermiston M.L., et al. Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young adults. Best Pract Res Clin Haematol. 2023; 36(1): 101449. DOI: 10.1016/j.beha.2023.101449.Алешина О.А., Гальцева И.В., Котова Е.С. и др. Результаты терапии острых Т-лимфобластных лейкозов/лимфом: данные многоцентрового проспективного рандомизированного исследования ОЛЛ-2016. Онкогематология. 2023; 18(1): 20–30. DOI: 10.17650/1818-8346-2023-18-1-20-30.Aleshina O.A., Galtseva I.V., Kotova E.S., et al. Treatment outcomes for acute T-lymphoblastic leukemias/lymphomas: data from the ALL-2016 multicenter prospective randomized trial. Onkogematologiya. 2023; 18(1): 20–30 (In Russian). DOI: 10.17650/1818-8346-2023-18-1-20-30.Patte C., Kalifa C., Flamant F., et al. Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-Bcell (lymphoblastic) lymphoma. Med Pediatr Oncol. 1992; 20(2): 105–13. DOI: 10.1002/mpo.2950200204.Patte C., Kalifa C., Flamant F., et al. Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-Bcell (lymphoblastic) lymphoma. Med Pediatr Oncol. 1992; 20(2): 105–13. DOI: 10.1002/mpo.2950200204.Amylon M.D., Shuster J., Pullen J., et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999 Mar; 13(3): 335–42. DOI: 10.1038/sj.leu.2401310.Amylon M.D., Shuster J., Pullen J., et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999 Mar; 13(3): 335–42. DOI: 10.1038/sj.leu.2401310.Gao Y.J., Pan C., Tang J.Y., et al. Clinical outcome of childhood lymphoblastic lymphoma in Shanghai China 2001–2010. Pediatr Blood Cancer. 2014 Apr; 61(4): 659–63. DOI: 10.1002/pbc.24848.Gao Y.J., Pan C., Tang J.Y., et al. Clinical outcome of childhood lymphoblastic lymphoma in Shanghai China 2001–2010. Pediatr Blood Cancer. 2014 Apr; 61(4): 659–63. DOI: 10.1002/pbc.24848.Sandlund J.T., Pui C.H., Zhou Y., et al. Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study. Leukemia. 2009; 23(6): 1127–30. DOI: 10.1038/leu.2008.400.Sandlund J.T., Pui C.H., Zhou Y., et al. Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study. Leukemia. 2009; 23(6): 1127–30. DOI: 10.1038/leu.2008.400.Uyttebroeck A., Suciu S., Plat G., et al. Dexamethasone (DEX) versus prednisone (PRED) in T-cell non Hodgkin lymphoma (T-NHL): results of the randomized phase III trial 58951 of the EORTC Children Leukemia Group. Br J Haematol. 2012; 159(1): 37.Uyttebroeck A., Suciu S., Plat G., et al. Dexamethasone (DEX) versus prednisone (PRED) in T-cell non Hodgkin lymphoma (T-NHL): results of the randomized phase III trial 58951 of the EORTC Children Leukemia Group. Br J Haematol. 2012; 159(1): 37.Hayashi R.J., Winter S.S., Dunsmore K.P., et al. Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children’s Oncology Group AALL0434. J Clin Oncol. 2020; 38(26): 3062–70. DOI: 10.1200/JCO.20.00531.Hayashi R.J., Winter S.S., Dunsmore K.P., et al. Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children’s Oncology Group AALL0434. J Clin Oncol. 2020; 38(26): 3062–70. DOI: 10.1200/JCO.20.00531.Teachey D.T., Devidas M., Wood B.L., et al. Children’s Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed TCell Acute Lymphoblastic Leukemia and Lymphoma. J Clin Oncol. 2022; 40(19): 2106–18. DOI: 10.1200/JCO.21.02678.Teachey D.T., Devidas M., Wood B.L., et al. Children’s Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed TCell Acute Lymphoblastic Leukemia and Lymphoma. J Clin Oncol. 2022; 40(19): 2106–18. DOI: 10.1200/JCO.21.02678.Поляцкин И.Л., Артемьева А.С., Криволапов Ю.А. Пересмотренная классификация ВОЗ опухолей гемопоэтической и лимфоидной тканей, 2017 (4-е издание): опухоли лимфоидной ткани. Архив патологии. 2019; 81(3): 59–65. DOI: 10.17116/patol20198103159.Polyatskin I.L., Artem’eva A.S., Krivolapov Yu.A. Revised WHO  classification of tumors of hematopoietic and lymphoid tissues, 2017 (4 th edition): lymphoid tumors. Archiv Patologii. 2019; 81(3): 59–65 (In Russian). DOI: 10.17116/patol20198103159.Jaffe E. S., Harris N. L., Stein H., et al. WHO Classification of Tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001. 352 pJaffe E. S., Harris N. L., Stein H., et al. WHO Classification of Tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001. 352 pVardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114(5): 937–51. DOI: 10.1182/blood-2009-03-209262.Vardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114(5): 937–51. DOI: 10.1182/blood-2009-03-209262.

The authors declare that there are no conflicts of interest present.